Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease.
暂无分享,去创建一个
B. Nordestgaard | J. Vestbo | A. Tybjaerg-hansen | P. Lange | M. Dahl | A. Tybjærg‐Hansen | J. Vestbo | B. Nordestgaard
[1] J. Hogg,et al. Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. , 2001, American journal of respiratory and critical care medicine.
[2] T. Welte,et al. Interleukin-6 and transforming growth factor-beta 1 control expression of cathepsins B and L in human lung epithelial cells. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[3] P. Barnes,et al. Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.
[4] J. Banchereau,et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages , 2000, Nature Immunology.
[5] W. V. Berghe,et al. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. , 2000, Biochemical pharmacology.
[6] M. Kitaichi,et al. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. , 2000, American journal of respiratory and critical care medicine.
[7] W. MacNee,et al. Oxidants/antioxidants and COPD. , 2000, Chest.
[8] D. Brenner,et al. Interleukin-6 Increases Rat Metalloproteinase-13 Gene Expression through Stimulation of Activator Protein 1 Transcription Factor in Cultured Fibroblasts* , 1999, The Journal of Biological Chemistry.
[9] D. Levy,et al. The association of chronic cough with the risk of myocardial infarction: the Framingham Heart Study. , 1999, The American journal of medicine.
[10] I. Kushner,et al. Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.
[11] V. Salomaa,et al. Symptoms of chronic bronchitis, haemostatic factors, and coronary heart disease risk. , 1999, Atherosclerosis.
[12] B. Nordestgaard,et al. ΔF508 heterozygosity in cystic fibrosis and susceptibility to asthma , 1998, The Lancet.
[13] P. Schnohr,et al. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. , 1998, The New England journal of medicine.
[14] E. Moore,et al. Interleukin-6 augments neutrophil cytotoxic potential via selective enhancement of elastase release. , 1998, The Journal of surgical research.
[15] K. Morgan,et al. Regulation of the serine proteinase inhibitor (SERPIN) gene alpha 1-antitrypsin: a paradigm for other SERPINs. , 1997, The international journal of biochemistry & cell biology.
[16] L. Martin,et al. Airway epithelium as an effector of inflammation: molecular regulation of secondary mediators. , 1997, The European respiratory journal.
[17] P. Enright,et al. Asthma and its association with cardiovascular disease in the elderly. The Cardiovascular Health Study Research Group. , 1996, The Journal of asthma : official journal of the Association for the Care of Asthma.
[18] S. Basili,et al. Hypercoagulability State in Patients with Chronic Obstructive Pulmonary Disease , 1994, Thrombosis and Haemostasis.
[19] P. Schnohr,et al. Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. , 1991, The European respiratory journal.
[20] P. Heinrich,et al. Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytes , 1989, FEBS letters.
[21] Shrestha Nk,et al. Chronic bronchitis and emphysema in Nepal. , 1980 .